The effect of vitamin D and magnesium supplementation on patients with COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; COVID-19; U07.1

• Registration Number: IRCT20210702051763N1
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 May 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

People aged 18-65
confirmation of Covid-19 infection by RT-PCR test
completing informed consent
less than 48 hours have passed since the patient was hospitalized
no skin or gastrointestinal allergies due to taking multivitamin supplements, vitamin D, and magnesium
people with more than 30 breaths per minute and less than 93% oxygen saturation in room air and sea level.

Exclusion Criteria

Pregnancy or lactation
take a daily multivitamin or take a vitamin D or magnesium supplement in the last month
participating in other clinical studies
renal failure or dialysis, severe liver disease or cirrhosis
known diagnosis of hypercalcemia
patients who discharged from the hospital less than 24 hours after the start of the intervention
history of kidney stones in the last year
transfer the patient to the ICU
baseline vitamin D levels above 80 ng/ml
baseline magnesium levels above 2.6 mg/dl.

Study & Design

• Study Type: interventional
• Study Design: Not specified